ACRS Aclaris Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1557746 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-59.3%
TTM net income YoY43.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR-33.2%
Net income 3-yr CAGR—
Margins
Gross margin79.2%
Operating margin-1,414.0%
Net margin-1,244.1%
FCF margin-1,176.6%
EBITDA margin-1,407.5%
Returns
ROE-55.5%
ROA-40.7%
ROIC (approx.)-59.3%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets22.8%
Debt / equity0.00x
Current ratio5.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.48M | $1.63M | $2.00M | $1.29M | $3.30M | $1.78M | $1.46M | $9.21M |
| Cost of revenue | $189,000 | $218,000 | $395,000 | $532,000 | $538,000 | $515,000 | $506,000 | $705,000 |
| Gross profit | $1.29M | $1.41M | $1.60M | $763,000 | $2.76M | $1.26M | $949,000 | $8.51M |
| R&D expense | $16.07M | $18.07M | $15.66M | $16.58M | $13.03M | $11.45M | $11.58M | $9.03M |
| SG&A expense | $6.04M | $6.05M | $6.74M | $5.58M | $4.87M | $5.39M | $6.14M | $4.95M |
| Operating income | -$21.34M | -$24.24M | -$22.19M | -$22.73M | -$17.15M | -$18.41M | -$18.08M | -$99.67M |
| Pretax income | — | — | — | -$19.80M | -$14.61M | -$15.43M | -$15.09M | -$96.55M |
| Net income | -$18.51M | -$21.50M | -$19.82M | -$19.80M | -$14.61M | -$15.43M | -$15.09M | -$96.55M |
| EBITDA | -$21.24M | -$24.13M | -$22.09M | -$22.63M | -$17.05M | -$18.31M | -$17.96M | -$99.53M |
| EPS (basic) | -0.12 | -0.15 | -0.15 | — | -0.12 | -0.13 | -0.12 | — |
| EPS (diluted) | -0.12 | -0.15 | -0.15 | — | -0.12 | -0.13 | -0.12 | — |
| Weighted avg. shares (diluted) | 149.45M | 142.74M | 128.81M | — | 122.62M | 122.58M | 122.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.39M | $19.17M | $28.66M | $19.96M | $25.26M | $25.40M | $30.36M | $24.57M |
| Short-term investments | $93.90M | $72.39M | $76.76M | $70.79M | $70.66M | $74.40M | $74.96M | $89.02M |
| Receivables | — | — | — | — | — | $194,000 | $250,000 | $318,000 |
| Current assets | $123.23M | $97.77M | $110.23M | $96.32M | $100.59M | $104.20M | $108.79M | $125.95M |
| PP&E, net | $624,000 | $664,000 | $750,000 | $761,000 | $811,000 | $868,000 | $942,000 | $1.01M |
| Total assets | $216.16M | $179.69M | $198.72M | $160.46M | $175.53M | $189.15M | $198.09M | $220.33M |
| Current liabilities | $24.22M | $28.24M | $27.37M | $28.64M | $25.63M | $26.84M | $21.51M | $31.60M |
| Total liabilities | $49.36M | $55.11M | $55.07M | $57.38M | $55.43M | $57.41M | $54.03M | $64.77M |
| Shareholders' equity | $166.80M | $124.58M | $143.65M | $103.08M | $120.10M | $131.74M | $144.07M | $155.55M |
| Shares outstanding | 150.83M | 139.82M | 139.65M | 120.50M | 108.34M | 108.33M | 108.27M | 107.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24.08M | -$19.85M | -$18.15M | -$13.13M | -$10.93M | -$9.99M | -$13.06M | -$8.94M |
| Capital expenditure | $13,000 | $58,000 | $13,000 | $24,000 | $23,000 | $21,000 | $43,000 | $0 |
| Free cash flow | -$24.09M | -$19.91M | -$18.16M | -$13.15M | -$10.96M | -$10.01M | -$13.10M | -$8.94M |
| Investing cash flow | -$33.22M | $10.26M | -$30.93M | $10.37M | $13.83M | $5.05M | $19.12M | -$88.72M |
| Financing cash flow | $58.52M | $91,000 | $57.78M | -$2.53M | -$3.04M | -$9,000 | -$275,000 | $74.58M |
| Depreciation & amortization | $100,000 | $107,000 | $102,000 | $102,000 | $100,000 | $100,000 | $128,000 | $143,000 |
| Stock-based compensation | $3.02M | $2.67M | $3.20M | $2.93M | $2.86M | $3.06M | $3.54M | $2.86M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.